Deciphering the molecular mechanisms of Maxing Huoqiao Decoction in treating pulmonary fibrosis via transcriptional profiling and circRNA-miRNA-mRNA network analysis.

[1]  Han Yang,et al.  MiR-29a-3p Improves Acute Lung Injury by Reducing Alveolar Epithelial Cell PANoptosis , 2022, Aging and disease.

[2]  H. Rothan,et al.  SARS-CoV-2 Infects Primary Neurons from Human ACE2 Expressing Mice and Upregulates Genes Involved in the Inflammatory and Necroptotic Pathways , 2022, Pathogens.

[3]  Y. Bhandary,et al.  Inflammatory mediators in various molecular pathways involved in the development of pulmonary fibrosis. , 2021, International immunopharmacology.

[4]  Hongjun Yang,et al.  A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine , 2021, Acta pharmaceutica Sinica. B.

[5]  Yan Wang,et al.  Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification , 2021, Journal of Ethnopharmacology.

[6]  Jianxin Chen,et al.  Deciphering the Pharmacological Mechanisms of Ma Xing Shi Gan Decoction against COVID-19 through Integrating Network Pharmacology and Experimental Exploration , 2020, Frontiers in Pharmacology.

[7]  Andreas C. Damianou,et al.  Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection , 2020 .

[8]  G. Hummer,et al.  Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity , 2020, Nature.

[9]  Ren Jing,et al.  Necroptosis in pulmonary macrophages mediates lipopolysaccharide-induced lung inflammatory injury by activating ZBP-1. , 2019, International immunopharmacology.

[10]  Hua Tang,et al.  Influenza Virus Infection Induces ZBP1 Expression and Necroptosis in Mouse Lungs , 2019, Front. Cell. Infect. Microbiol..

[11]  M. Kool,et al.  Inflammation and immunity in IPF pathogenesis and treatment. , 2019, Respiratory medicine.

[12]  M. Kool,et al.  Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end , 2018, European Respiratory Journal.

[13]  D. Lederer,et al.  Idiopathic Pulmonary Fibrosis. , 2018, The New England journal of medicine.

[14]  C. Oancea,et al.  The reliability of lung ultrasound in assessment of idiopathic pulmonary fibrosis , 2018, Clinical interventions in aging.

[15]  B. Han,et al.  circHECTD1 promotes the silica-induced pulmonary endothelial–mesenchymal transition via HECTD1 , 2018, Cell Death & Disease.

[16]  S. Kameoka,et al.  Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease. , 2016, JCI insight.

[17]  Wenbo Tang,et al.  Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume , 2016, Thorax.

[18]  H. Pavenstädt,et al.  Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog , 2016, Nature Reviews Nephrology.

[19]  G. Labarca,et al.  Correction: Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis , 2015, PloS one.

[20]  M. Nireekshan Kumar,et al.  MicroRNA-326 regulates profibrotic functions of transforming growth factor-β in pulmonary fibrosis. , 2014, American journal of respiratory cell and molecular biology.

[21]  P. Pandolfi,et al.  A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.

[22]  Arthur S Slutsky,et al.  An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. , 2011, American journal of respiratory cell and molecular biology.

[23]  M. Gershwin,et al.  Idiopathic Pulmonary Fibrosis—an Epidemiological and Pathological Review , 2011, Clinical reviews in allergy & immunology.

[24]  J. Golden,et al.  Progression of native lung fibrosis in lung transplant recipients with idiopathic pulmonary fibrosis. , 2010, Respiratory medicine.

[25]  Y. Castier,et al.  Survival After Bilateral Versus Single-Lung Transplantation for Idiopathic Pulmonary Fibrosis , 2009, Annals of Internal Medicine.

[26]  K. Ota.  [Diagnosis and treatment of idiopathic pulmonary fibrosis]. , 2007, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[27]  Shandra L. Protzko,et al.  AMERICAN THORACIC SOCIETY DOCUMENTS An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline , 2015 .